CRI Worldwide

• News
• Publications

Pharsight and CRI Worldwide Establish Alliance
^{CRI Staff, 7/22/2008}

Pharsight Corporation (Nasdaq:PHST), a leading provider of software, strategic consulting, and regulatory services for optimizing clinical drug development, and CRI Worldwide, a leading provider of clinical research services to the global pharmaceutical and biotech industries, today announced that they have formed an alliance to offer combined services including trial design, simulation, execution, analysis and reporting. The alliance provides a broader solution to customers and addresses the growing need for drug development companies to improve the efficiency in their performance and analysis of clinical trials.

"Our clients recognize the value of linking CRI's clinical trial execution capability with Pharsight's state-of-the-art design, analysis, and reporting expertise," said Ken King, chief executive officer of CRI Worldwide. "The client can expect faster delivery of results, a more informative trial, and a higher likelihood of success."

"Pharsight is a world leader in the modeling, analysis and reporting of data originating in clinical pharmacology trials," said Shawn O'Connor, president, chief executive officer, and chairman of Pharsight. "Our alliance with CRI will allow us to get involved earlier in the process when the client is contracting with the clinic and the trial is still being designed. On the back end, we will work with CRI to ensure seamless data transfers and rapid turnaround of regulatory analysis and reporting."

About Pharsight Corporation

Pharsight Corporation develops and markets integrated products and services that enable pharmaceutical and biotechnology companies to achieve significant and enduring improvements in the development and use of therapeutic products. The company's goal is to help customers reduce the time, cost and risk of drug development, as well as optimize the post-approval marketing and use of pharmaceutical products.

Pharsight's approach enhances the fundamental element of drug development success: strong decision-making. By adopting the Pharsight approach, customers acquire a new decision-making process with the potential to systematically improve every level and phase of their business and scientific processes. Pharsight Corporation is headquartered in Mountain View, California. Information about Pharsight is available at http://www.pharsight.com.

Back to the news section or top of the page